Since it is April Fools day, I thought it fitting to ask
Since it is April Fools day, I thought it fitting to ask everyone a question. What will be the next fiasco to delay LL from saving lives? Will it be a blantant rejection from the FDA? Will they try to bleed us of cash through additional trials? Will they decide all therapuetics given by shots are now illegal because needles are sharp and can be used to stab people?
How will they manipulate the rules to keep Americans from being helped by LL while bending the rules to give inferior drugs unwarranted approval?
This is actually a fun exercise and is a way to reduce the frustration with the games the FDA is playing with CYDY.
Another point that is interesting to observe is how much BS can the government get away with?
So many people have suffered needlessly from this virus. It is blatantly obvious that saving American lives by any means neccesary is not their concern.
This in turn leads to another fun activity to watch, how much covering up will mainstream media and social media perform in an attempt to keep people from learning about what is happening right under their noses?
With all this being said I am going to give my best guess at the next FDA excuse for keeping lives from being saved...
My kick the can down the road theory is in fact that the FDA outlaws needles which means we will have to make LL in a pill form, which will then require all new trials for LL at FDA mandated dosing requirements and intervals.
12 months later, when we finally jump through all the trial hoops and are still proven to be the most effective and safe therapeutic in existence, and after we have shown stat significance and fashioned our trials to be FDA BS proof, the FDA will then say that LL can not be distributed in pill form because pills present a choking hazard. You see 1 out of every 35,000,000 US residents die from choking on pills each year and it is the FDA's duty to protect the US citizens and keep them alive. Therefore we will not recieve approval.
All of this would be a funny April fools day joke if it was not actually looking more and more likely that the FDA would try to pull this kind of shit if it meant giving more time for BP to develop a competing therapeutic...
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Nanjing Hosts Cultural Dialogue on the Yangtze Right in the heart of Nanjing, there's been a buzz about preserving the past while facing the future head-on. Picture this: intellectual heavyweights from around the Yangtze basin gathering not in some plush conference room, but on the river itself. On November 10, 2026, the meeting of minds set sail, departing from Zhongshan...
Continue Reading
When they say history's for sale, I guess they weren't kidding, were they? Here's a gem from the annals of baseball that might just light up your investment senses—the first Ted Williams-signed baseball from his early days with the Boston Red Sox in 1937 is up for auction. If you're a collector, or even just a baseball romantic, this one's hard to ignore. A Piece of...
Continue Reading
Upcoming Unveiling: Pearl Diver's Latest Financials Heads up, folks. November 16 can't come soon enough for those keeping tabs on Pearl Diver Credit Company Inc. (NYSE: PDCC, PDPA). The bigwigs over there are planning to spill the beans on their third quarter 2026 financial results. They'll kick things off before the market even has its first cup of java on Monday morning...
Continue Reading
Frothy Celebrations for Passenger Princesses There's a fresh hue tinkling across the drive-thru circuit this November, dipped in audacity and powered by social trend winds. Dutch Bros, that lively drive-thru kingpin, is capitalizing on a viral TikTok trend by rolling out the pink carpet for its third annual National Passenger Princess Day. And this ain't just a one-day...
Continue Reading
A Breakthrough Carve-Out Success Story A story that starts with a carve-out and winds up with a strategic sale reeks of experience, and that's precisely what Southfield Capital did with TFS. Back in 2024, they snagged TFS through a carve-out and didn't just sit on it like a lazy trader watching stock tickers race by. Instead, they pushed the envelope with smart...
Continue Reading
A Tactical Addition to American Global Strategies The chessboard of global security just saw a savvy new player join American Global Strategies (AGS). Rachel Noble, a name that echoes through the halls of Australia's national security apparatus, has joined AGS as Senior Advisor. This isn't your garden-variety hire—this is a strategic power move. From Down Under to the...
Continue Reading
Taking Aim at a Deadly Habit Everyone's got that gut feeling when a day-long meeting runs over or you're stuck in traffic — impatience morphed with slow burn menace. Now picture a whole campaign gunning for that vibe but in the hands of the young folks, those from 21 to 34. That's what we're talking about here, with the Ad Council and NHTSA serving up some fresh public...
Continue Reading
OpenAssets Carves a Niche in Abu Dhabi OpenAssets has just staked a claim in the Middle East by setting up its headquarters in the Abu Dhabi Global Market (ADGM). Picture this: a digital asset infrastructure provider unfurling its wings in one of the most dynamic economic landscapes—it's like watching a rookie clinch the game at the stock pit. But there's more, folks....
Continue Reading
Leadership Takes an Unexpected Turn at Capital Properties When the helm of a ship faces turbulence, everyone's eyes turn to the captain. In the case of Capital Properties, Inc., their captain, Chairman, CEO and President Robert H. Eder, has hit a personal snag, diagnosed with cancer but determined to steer steady despite the storm brewing within. A Glance at Capital...
Continue Reading
Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...
Continue Reading
Top 5 Most Recently Viewed Articles
Kulicke & Soffa Declares $0.205 Quarterly Dividend Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC) has taken a significant step by declaring a quarterly dividend of $0.205 for each share of its common stock. This decision reflects the company’s ongoing commitment to delivering value to its shareholders. The dividend payment is set to occur on a future date, ensuring...
Continue Reading
Exciting New Collaboration to Revive Amazon Ecosystem In a significant step towards environmental restoration, private equity-backed reforestation startup re.green has formed a partnership with Agro Penido. Together, they're embarking on an ambitious project to rejuvenate 600 hectares of land using native species from the Amazon rainforest. This collaboration not only...
Continue Reading
XellSmart's Breakthrough in Regenerative Medicine XellSmart Biopharmaceutical has made significant strides in the field of regenerative medicine with the official announcement of its allogeneic iPSC-derived cell therapy geared towards treating spinal cord injuries (SCI). This therapy has received the green light from regulatory authorities, paving the way for a...
Continue Reading
Anticipating the PPG Industries Earnings Report PPG Industries (PPG) is gearing up for its next quarterly earnings announcement, creating buzz among investors eager for insights into its financial performance. The anticipated date for this announcement is fast approaching, sparking interest and speculation. Analysts have set expectations, projecting that PPG Industries...
Continue Reading
Important Notice for CrowdStrike Holdings Shareholders About a Class Action The Gross Law Firm has issued a crucial notice to shareholders of CrowdStrike Holdings, Inc. (NASDAQ: CRWD) about a possible class action lawsuit. If you bought shares of CRWD during the relevant class period, you're encouraged to reach out regarding a potential lead plaintiff appointment....
Continue Reading
